Showing results (311-320 of 617) with videos related to

Sort By:
Pageof 62
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 24, 2008
Improved reflux monitoring in the acute gastroesophageal reflux porcine model using esophageal multichannel intraluminal impedance measurementBeat Peter Müller-Stich, Arianeb Mehrabi, Hannes Götz Kenngott, et al.
Haematologica|June 27, 2012
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 casesSusanne Schnittger, Ulrike Bacher, Tamara Alpermann, et al.
British Journal of Haematology|June 26, 2020
Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosisFiorenza Barraco, Richard Greil, Raoul Herbrecht, et al.
Blood|September 4, 2004
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Richard M Stone, Daniel J DeAngelo, Virginia Klimek, et al.
Leukemia Research|September 15, 2022
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclaxJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Blood|July 11, 2013
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus reportAyalew Tefferi, Francisco Cervantes, Ruben Mesa, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 24, 2021
Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical ReviewTheo Gülen, Cem Akin, Patrizia Bonadonna, et al.
Leukemia & Lymphoma|October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitorsJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Cancer|June 30, 2012
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock, Jeffrey L Johnson, Richard M Stone, et al.
Blood Advances|December 12, 2022
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemiaShai Shimony, Yiwen Liu, Yannis K Valtis, et al.
Pageof 62